PAK1 and hepatocellular carcinoma: Our finding that ATRA enhanced the inhibition of HCC by Sorafenib via the downregulation of PAK1 further supported the argument that inhibition of PAK1 attenuates Sorafenib resistance and promotes its therapeutic efficacy in either monotherapy or combination therapy.